Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint inhibitor immunotherapy, significantly boosted anti-tumour activity in mouse ...

Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.

Explore global unity in times of uncertainty with OS Therapeutics' Paul Romness and EVERSANA's Farah Ahmad. Watch the video interview for valuable perspectives and ideas from BIO 2025.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million.

BioNTech’s ASCO 2025 abstracts showcase advances in oncology, from bispecific antibodies to mRNA immunotherapies. Annemarie Hanekamp shares insights on pipeline progress—watch now!

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

Replimune has announced that the FDA has issued a Complete Response Letter regarding the Biologics License Application for RP1 in combination with nivolumab for the treatment of advanced melanoma.

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

Pfizer's vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a ...

Three key lessons the past five years of challenges and experience have taught us that we can use to move the biosimilars market forward.